Indaptus Therapeutics (INDP) provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week’s earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial. Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients demonstrating stable disease. Additionally, Decoy20 triggered short-term increases in multiple key immune system biomarkers, which play a crucial role in activating the body’s natural defenses against cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDP:
- Indaptus Therapeutics initiates Phase 1 study of Decoy20
- Buy Recommendation for Indaptus Therapeutics: Promising Phase 1 Study and Financial Stability Boost Confidence
- Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year
- Indaptus Therapeutics expands patent portfolio in China, Japan, Israel
- Indaptus Therapeutics files to sell 10M shares of common stock for holders
Questions or Comments about the article? Write to editor@tipranks.com